# Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators

**Authors:** Duraisamy Kempuraj, Ramasamy Thangavel, Evert Yang, Sagar Pattani, Smita Zaheer, Donna A. Santillan, Mark K. Santillan, Asgar Zaheer

PMC · DOI: 10.1371/journal.pone.0135776 · PLoS ONE · 2015-08-14

## TL;DR

This study shows that proteins and toxins linked to Parkinson's disease can activate mast cells and release inflammatory mediators, suggesting a new role for mast cells in neurodegenerative diseases.

## Contribution

The novel finding is that GMF, MPP+, and α-synuclein activate mast cells and glia, releasing inflammatory mediators relevant to Parkinson's disease.

## Key findings

- GMF, MPP+, and α-synuclein induce release of inflammatory mediators like IL-1β and TNF-α from mast cells and astrocytes.
- Mast cells express GMF and respond to IL-33, suggesting a feedback loop in neuroinflammation.
- Cocultures of mast cells and astrocytes show enhanced proinflammatory mediator release compared to individual cultures.

## Abstract

Parkinson’s disease (PD) is characterized by the presence of Lewy bodies and degeneration of dopaminergic neurons. 1-methyl-4-phenylpyridinium (MPP+), a metabolite of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Lewy body component α-synuclein activates glia in PD pathogenesis. Mast cells and glia maturation factor (GMF) are implicated in neuroinflammatory conditions including Multiple Sclerosis. However, the role of mast cells in PD is not yet known. We have analyzed the effect of recombinant GMF, MPP+, α-synuclein and interleukin-33 (IL-33) on mouse bone marrow-derived cultured mast cells (BMMCs), human umbilical cord blood-derived cultured mast cells (hCBMCs) and mouse brain-derived cultured astrocytes by quantifying cytokines/chemokines released using ELISA or by detecting the expression of co-stimulatory molecules CD40 and CD40L by flow cytometry. GMF significantly released chemokine (C-C motif) ligand 2 (CCL2) from BMMCs but its release was reduced in BMMCs from GMF knockout mice. GMF, α-synuclein and MPP+ released IL-1β, β-hexosaminidase from BMMCs, and IL-8 from hCBMCs. GMF released CCL5, and IL-33- induced the expression of GMF from hCBMCs. Novel GMF expression was detected in hCBMCs and BMMCs by immunocytochemistry. GMF released tumor necrosis factor-alpha (TNF-α) from mouse astrocytes, and this release was greater in BMMC- astrocyte coculture than in individual cultures. Flow cytometry results showed increased IL-33 expression by GMF and MPP+, and GMF-induced CD40 expression in astrocytes. Proinflammatory mediator release by GMF, MPP+ and α-synuclein, as well as GMF expression by mast cells indicate a potential therapeutic target for neurodegenerative diseases including PD.

## Linked entities

- **Proteins:** GMFB (glia maturation factor beta), IL33 (interleukin 33), CD40 (CD40 molecule), CD40LG (CD40 ligand)
- **Chemicals:** 1-methyl-4-phenylpyridinium (PubChem CID 39484), MPP+ (PubChem CID 39484), doxorubicin (PubChem CID 31703), tumor necrosis factor-alpha (PubChem CID 44356648), CCL2 (PubChem CID 6432145), IL-8 (PubChem CID 169410440)
- **Diseases:** Parkinson’s disease (MONDO:0005180), Multiple Sclerosis (MONDO:0005301)
- **Species:** Mus musculus (taxon 10090), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, Il3 (interleukin 3) [NCBI Gene 16187] {aka BPA, Csfmu, HCGF, Il-3, MCGF, PSF}, C5ar1 (complement component 5a receptor 1) [NCBI Gene 12273] {aka C5aR, C5r1, Cd88, D7Msu1}, Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, Crh (corticotropin releasing hormone) [NCBI Gene 12918] {aka CRF, Gm1347}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, F2rl1 (F2R like trypsin receptor 1) [NCBI Gene 14063] {aka Gpcr11, PAR-2, Par2}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, OGA (O-GlcNAcase) [NCBI Gene 10724] {aka MEA5, MGEA5, NCOAT}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, Tlr2 (toll-like receptor 2) [NCBI Gene 24088] {aka Ly105}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, Cd40lg (CD40 ligand) [NCBI Gene 21947] {aka CD154, CD40-L, Cd40l, HIGM1, IGM, IMD3}, CD34 (CD34 molecule) [NCBI Gene 947], Cd40 (CD40 antigen) [NCBI Gene 21939] {aka Bp50, GP39, HIGM1, IGM, IMD3, T-BAM}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Ngf (nerve growth factor) [NCBI Gene 18049] {aka Ngfb, beta-NGF}, Cd34 (CD34 antigen) [NCBI Gene 12490], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Kitl (kit ligand) [NCBI Gene 17311] {aka Clo, Con, Gb, Kitlg, Mgf, SCF}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, Tac1 (tachykinin 1) [NCBI Gene 21333] {aka 4930528L02Rik, NK-1, NK1, Nkna, PPT-A, PPTA}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Tpsab1 (tryptase alpha/beta 1) [NCBI Gene 100503895] {aka MMCP-7, Mcp-7, Mcp7, Mcpt7}, IL3 (interleukin 3) [NCBI Gene 3562] {aka IL-3, MCGF, MULTI-CSF}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, GMFB (glia maturation factor beta) [NCBI Gene 2764] {aka GMF}, Gmfb (glia maturation factor, beta) [NCBI Gene 63985] {aka 3110001H22Rik, 3110001O16Rik, D14Ertd630e}, Il33 (interleukin 33) [NCBI Gene 77125] {aka 9230117N10Rik, Il-33, Il1f11, NF-HEV}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Snca (synuclein, alpha) [NCBI Gene 20617] {aka NACP, alpha-Syn, alphaSYN}, Oga (O-GlcNAcase) [NCBI Gene 76055] {aka Hy5, Mgea5, Ncoat}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, Ighv1-9 (immunoglobulin heavy variable 1-9) [NCBI Gene 668478] {aka Gm16697, Igg2a}, Prom1 (prominin 1) [NCBI Gene 19126] {aka 4932416E19Rik, AC133, CD133, Prom, Prom-1, Proml1}
- **Diseases:** toxicity (MESH:D064420), MS (MESH:D009103), Alzheimer's disease (MESH:D000544), neuroinflammation (MESH:D000090862), neuron (MESH:D009410), neurotoxic cytokines (MESH:D000080424), PD (MESH:D010300), mitochondrial dysfunctions (MESH:D028361), necrosis (MESH:D009336), neurotoxic mediator (MESH:C567355), neurotoxic (MESH:D020258), Lewy bodies (MESH:D020961), neuronal dysfunction (MESH:D009461), dysfunction of mitochondria (MESH:C564971), EAE (MESH:D004681), cognitive impairment (MESH:D003072), neurodegeneration (MESH:D019636), cell (MESH:D002292), inflammation (MESH:D007249)
- **Chemicals:** prostaglandins (MESH:D011453), ABC (MESH:C106538), methanol (MESH:D000432), PD (MESH:D010165), dopamine (MESH:D004298), SDS (MESH:D012967), NP-40 (MESH:C010615), EDTA (MESH:D004492), L-glutamine (MESH:D005973), acetone (MESH:D000096), reactive nitrogen species (MESH:D026361), Triton-X-100 (MESH:D017830), serotonin (MESH:D012701), PBS (MESH:D007854), citrate (MESH:D019343), 2-Mercaptoethanol (MESH:D008623), NaCl (MESH:D012965), Toluidine blue (MESH:D014048), DAB (MESH:C000469), Dulbecco's Modified Eagle Medium Nutrient Mixture F-12 (-), histamine (MESH:D006632), leukotrienes (MESH:D015289), NO (MESH:D009614), glycine (MESH:D005998), Penicillin (MESH:D010406), nitric oxide (MESH:D009569), RNS (MESH:D011886), CO2 (MESH:D002245), ROS (MESH:D017382), citrate phosphate dextrose (MESH:C007077), Trypan blue (MESH:D014343), 1- methyl -4- phenyl -1,2,3,6-tetrahydro pyridine (MESH:D015632), deoxycholate (MESH:D003840), lipid (MESH:D008055), Streptomycin (MESH:D013307), 1-Methyl-4-Phenylpyridinium (MESH:D015655), DPBS (MESH:C012939),  (MESH:D019013),  (MESH:D023201),  (MESH:D020904),  (MESH:D016209)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** AC133+ — Mus musculus (Mouse), Hybridoma (CVCL_G632), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), C57BL — Homo sapiens (Human), Burkitt lymphoma, Cancer cell line (CVCL_C152), hCBMCs — Homo sapiens (Human), Transformed cell line (CVCL_VI06)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4537263/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4537263/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC4537263/full.md

---
Source: https://tomesphere.com/paper/PMC4537263